NATCO Pharma Introduces Generic Blood Cancer Drug in US Market

NATCO Pharma has declared the official release of its generic Pomalidomide capsules in the United States, which is a milestone for the company at the beginning of this year.

The prescription is stated to be used to treat adult patients diagnosed with blood and bone marrow cancer and was developed in collaboration with Breckenridge Pharmaceutical, Inc.

It is a generic version of Pomalyst, which is manufactured by Celgene, and it comes in 4 strengths, 1mg, 2mg, 3 mg and 4mg. Distribution of pomalidomide capsules is predominantly done in specialty pharmacies and clinics with the hopes of enhancing access to life-saving treatment for cancer patients.

Rajeev Nannapaneni, Vice Chairman and CEO of NATCO Pharma, commented on the launch, saying, "This further strengthens our oncology and specialty portfolio in the US. The launch highlights our commitment to our mission of making specialty medicines accessible to all patients worldwide."

Nannapaneni also expressed optimism for the future, adding, "We look forward to bringing more such complex and specialty products to the market in the coming years."

Brian Guy, President and Chief Commercial Officer of Breckenridge Pharmaceutical, emphasized the importance of affordability, stating, "Breckenridge's launch of Pomalidomide capsules delivers a high-quality, affordable generic solution, supported by copay assistance for eligible patients to help reduce treatment delays and ensure continuity of care."

The novel product is especially useful in patients with multiple myeloma who have failed to respond to other treatment methods. Pomalidomide capsules are also provided as a treatment for the Kaposi sarcoma of AIDS. By industry sales, the drug was projected to have sales of $3.2 billion in the US during the 12 months that ended in September 2025.

NATCO Pharma has also assumed that it shares a 180-day exclusivity in marketing the drug due to the disclosures by the US Food and Drug Administration (FDA). The company's launch of generic Pomalidomide in the US strengthens its global presence, potentially paving the way for future availability in India. This success could enhance brand recognition and lead to more affordable cancer treatments in the domestic market.